STAT+: Spain’s antitrust regulator fines drugmaker for ‘excessive’ pricing of a rare disease drug
Antitrust regulators in Spain have fined a drugmaker $10.6 million for years of “excessive” price…
Category: Pharmalot
STAT+: More drugmakers are expanding access in poorer countries, but progress continues to lag overall
For the first time, many of the world’s largest pharmaceutical companies are taking concrete steps…
‘A very worrying scenario’: Internal documents on India Covid-19 vaccine raise troubling questions about approval process
As the Covid-19 pandemic spread across the world two years ago, one of India’s leading…
STAT+: Pharmalittle: Roche Alzheimer’s drug fails in two studies; Indivior bets on addiction market with deal to buy Opiant
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Lilly says fake Twitter account offered free insulin; AstraZeneca drops plans for Covid shot in the U.S.
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Viatris executive is charged with insider trading scheme involving a friend and former colleague
A high-ranking Viatris executive was charged with insider trading for tipping a friend and former…
STAT+: Pharmalittle: Biogen hires Viehbacher as its CEO; new dengue vaccine rolled out amid safety concerns
Top of the morning to you, and a fine one it is. Crystal clear blue…
STAT+: Pharmalittle: ADC backs off accelerated approval after FDA demands confirmatory trial; explaining the Supreme Court’s split on drug-patent cases
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: The U.S. Supreme Court will review a contentious Amgen patent case, but not one involving Bristol. Why?
In a surprising move, the U.S. Supreme Court rejected a bid by a Bristol Myers…
STAT+: Pharmalittle: Biogen mulls new options in its CEO hunt; NIH starts contacting universities about overdue trial results
Rise and shine, everyone, another busy day is on the way. This is especially true…
.jpg)
STAT+: After years of lax oversight, the NIH is starting to contact institutions about unreported clinical trial results
In recent weeks, the U.S. National Institutes of Health has begun emailing academic institutions that…
STAT+: Amid concerns over U.S. democracy, pharma helped finance committees that support election deniers
As Americans head to the polls, some candidates continue to deny the results of the…
STAT+: Pharmalittle: Some Lilly workers want transfers due to Indiana abortion law; GSK cancer drug flops in late-stage study
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: U.S. Supreme Court gives Amgen a boost by agreeing to review a closely watched patent case
In a boost for Amgen, the U.S. Supreme Court on Friday agreed to hear a…
STAT+: A ‘blank check’: Bill to boost antibiotic development blasted as a ‘flawed’ giveaway to pharma
Amid mounting concern over antibiotic resistance, a coalition of academics and advocacy groups is urging…
STAT+: Pharmalittle: Europe approves a Sanofi and AstraZeneca RSV shot; CDC updates opioid prescribing guidelines
And so, another working week will soon draw to a close. Not a moment too…
STAT+: A leaked version of a U.K.-India free trade deal sparks alarm over access to medicines
A leaked draft version of a trade agreement being negotiated between the United Kingdom and…
STAT+: Pharmalittle: Moderna must face patent claims over its Covid-19 vaccine; Pfizer and BioNTech testing combo Covid and flu shot
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Pharmalittle: FDA panel urges improved regulation of pulse oximeters; CVS Health agrees to $5 billion settlement over opioid lawsuits
Good morning from San Diego. I’m Jonathan Wosen, STAT’s West Coast biotech reporter, and I’m…
STAT+: Pharmalittle: Pfizer maternal RSV vaccine meets pivotal study’s goal; Lilly cuts its annual profit forecast
Tumble out of bed and stumble to the kitchen, pour myself a cup of ambition,…
STAT+: Pharmalittle: FDA advisers vote down pediatric brain cancer drug; AbbVie drops out of psoriasis partnership
Good morning, and welcome to a spooky edition of Pharmalittle. It’s Jason Mast here, filling…
STAT+: Pharmalittle: Drugmaker raises price of old chemo med 10-fold amid shortages; Alnylam cites drug-price law in halting trial
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Drugmaker raises the price of an old chemo medicine tenfold amid persistent shortages
Amid sporadic shortages of a drug that is essential in preparing patients for lifesaving, cancer-fighting…
STAT+: Pharmalittle: Italy probes Pfizer over profit transfers; FDA postpones meeting for OTC birth control pill
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Pharmalittle: White House pharma help in plan to combat hepatitis C; J&J blood cancer drug will cost $39,500 a month
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Merck fined $39 million by Spain’s antitrust regulator for ‘serious’ violation
The antitrust regulator in Spain has fined Merck approximately $39 million for preventing a competitor…
STAT+: Pharmalittle: Online prescribing prompts scrutiny and concern; FDA is pushed to approve OTC birth control pills
Top of the morning to you. Gray skies are hovering once again over the Pharmalot…
STAT+: Pharmalittle: Merck suddenly finds Ebola vaccine doses in its freezers; drugs studied to combat women’s midlife mood swings
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Pfizer plans to quadruple price of its Covid-19 vaccine; pharma pushed to tie exec compensation to access to meds
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Dozens of institutional investors urge drugmakers to link executive compensation to access to medicines
Three dozen institutional investors are urging the boards at several of the world’s largest pharmaceutical…
STAT+: Novartis agrees to license a best-selling cancer drug to dozens of low- and middle-income countries
Amid a push to widen access to medicines to poor countries, Novartis has reached an…
STAT+: How one pharma insider sees the drug pricing reform law: the impact will ‘vary by product and by company’
After years of stops and starts, a law was finally passed in Congress this summer…
STAT+: Pharmalittle: Pharma tries to blunt Medicare power to negotiate prices; FDA panel supports withdrawal of premature birth drug
Top of the morning to you. Another deliciously shiny day is unfolding over the Pharmalot…
STAT+: FDA panel votes that a controversial premature birth medication should be withdrawn
After an extraordinary three-day hearing, an expert panel of advisers to the U.S. Food and…
STAT+: Pharmalittle: Merck KGaA probed by French court for misleading info; former Genentech scientists given prison terms over trade-secret theft
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: How many? A new analysis finds 1.3 million American adults rationed insulin due to cost
Amid ongoing controversy over the cost of insulin, a new analysis finds that approximately 1.3…
STAT+: Pharmalittle: J&J will cut its workforce; pharma gave Dems money despite threats over Medicare drug-price negotiation
Top of the morning to you. Another busy day is unfolding on the Pharmalot satellite…
STAT+: Pharmalittle: BioNTech eyes cancer vaccine before decade’s end; Pfizer asks Supreme Court to review copay programs
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: European Prosecutor’s Office confirms it’s investigating European Union Covid vaccine contracts
In an unusual step, the European Public Prosecutor’s Office (EPPO) confirmed it has opened an…
STAT+: Lawmakers push NIH to disclose steps being taken to ensure clinical trial results are reported
A group of Republican senators is demanding to know what steps the U.S. National Institutes…
STAT+: Pharmalittle: Biden to sign executive order to push drug costs down; big grocers get bad grades for antibiotic policies
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Several big U.S. grocery chains are failing to stop antibiotic overuse in their meat supply chains
Amid rising concern over antibiotic resistance, a new report finds that a dozen of the…
STAT+: AstraZeneca is fined by South Korea for an anticompetitive deal over a cancer drug
South Korea’s anti-trust regulator has fined AstraZeneca and a local generic drugmaker a total of…
STAT+: Pharmalittle: GSK vaccine for RSV was effective in study of older adults; Eisai is confident of U.S. approval of its Alzheimer’s drug
Hello, everyone, and how are you today? Cloudy skies are hovering this morning over the…
STAT+: FDA and large compound pharmacies settle a long-running dispute over a key list for ingredients
The U.S. Food and Drug Administration and a trade group that represents large compound pharmacies…
STAT+: Pharmalittle: Walmart joins rivals in entering clinical trial work; Maiden Pharma failed to do quality tests on cough syrups
Top of the morning to you, and a fine one it is. After all, there…
STAT+: Pharmalittle: BIO CEO resigns amid board disagreements; Pfizer exec denies allegations over EU Covid-vaccine deal
Good morning, everyone, and how are you today? We are doing just fine thank you,…
STAT+: European Commission says preliminary findings indicate Teva violated antitrust rules
After three years of probing, the European Commission has reached a preliminary decision that Teva…
STAT+: Merck’s Covid-19 pill was no better than placebo in lowering the risk of hospitalization
A Merck pill used to combat Covid-19 failed to demonstrate it can lower the risk…
STAT+: Pharmalittle: Medicare can still penalize drugmakers for hiking prices to privately insured patients; FDA explains push to withdraw premature-birth drug
And so, another working week will soon draw to a close. Not a moment too…